Organization
Nashville, TN
25 abstracts
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Tennessee Oncology, PLLC,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Flat dose intravenous immunoglobulin (IVIG) for primary infection prophylaxis after CAR-T for B-cell non-Hodgkin lymphoma (B-NHL).Org: Vanderbilt University Medical Center, Nashville, TN,
Abstract
A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Washington University School of Medicine in St Louis, St. Louis, MO, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Phase I/II trial of gabapentin plus intranasal ketamine for the prevention and treatment of pain in patients undergoing radiotherapy for head and neck cancer.Org: Vanderbilt University Medical Center, Nashville, TN,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
Lost in translation? Information exchange during breast cancer care and implications for technology design.Org: Vanderbilt University Medical Center, Nashville, TN,
Abstract
Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.Org: James Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Columbus, OH, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.Org: Fred Hutchinson Cancer Research Center, Seattle, WA, American Society of Clinical Oncology, Alexandria, VA, Friends of Cancer Research, Washington, DC,
Abstract
CT radiomic signature to predict overall survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma.Org: Emory University, Atlanta, GA, USA, Atlanta, GA, Cleveland Clinic Taussig Cancer Instititute, Cleveland, OH, Emory University Hospital,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).Org: Harvard Medical School, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center, Houston, TX,
Abstract
Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Vanderbilt University Medical Center, Nashville, TN, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.Org: Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Nashville, TN, EQRx, Cambridge, MA,
Abstract
A prospective study evaluating the association of patient-reported outcomes with activity level and sleep patterns in sarcoma survivors.Org: Vanderbilt University Medical Center, Nashville, TN, Vanderbilt-Ingram Cancer Center, Vanderbilt Ingram Cancer Center, Division of Epidemiology and Community Health,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,